Geron (GERN) Q3 2026 earnings review
Geron's blood-cancer drug demand accelerates, but its second trial fails
Geron, the maker of the blood-cancer drug RYTELO, turned its first quarterly profit and added cash even as its second major clinical trial failed. Product revenue reached $60 million as quarter-over-quarter demand growth doubled to 10% on orders from community clinics. Chief executive Harout Semerjian cut the full-year operating expense plan by $10 million and started a European rollout in Germany, while keeping the full-year revenue target at the middle-to-high end of $220 million to $240 million.
| RYTELO net product revenue | $60.1M +5% from last quarter (+27% from a year ago) |
|---|---|
| RYTELO demand growth | +10% from last quarter (+5% in Q2) |
| Net income | $1.4M -$18.4M net loss a year ago |
| Full-year operating expense plan | Cut $10M now $220–230M; revenue plan kept at $220–240M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stronger U.S. demand and a profitable cost base offset the loss of the company's main pipeline expansion. An independent committee recommended stopping the Phase 3 myelofibrosis trial for lack of survival benefit, and Geron will not seek approval in that disease. That leaves the business reliant on lower-risk myelodysplastic syndromes, where a second straight quarter of inventory charges also weighed on production costs.
The question now is whether community clinics can drive RYTELO sales toward the $240 million top of the plan without a second approved disease. If third-quarter demand turns into fourth-quarter shipments, revenue will climb; if wholesaler timing or price discounts hold sales back, fourth-quarter revenue will stay near the $61 million middle of the range by our math. Fourth-quarter product revenue and 2027 targets will settle it.
🐂 Bull Case
Community Doctors Double Quarterly Demand Growth
Geron sells RYTELO, an intravenous drug for lower-risk myelodysplastic syndromes (LR-MDS), a blood cancer that causes severe anemia. Demand growth had slowed for two straight quarters, falling from 9% in the fourth quarter of last year to 5% in the second quarter. In the third quarter, demand grew 10% from the previous quarter.
- RYTELO net product sales: $60.1 million, up 4.6% from last quarter and 27.5% from a year ago
- Underlying demand: up 10% from last quarter, compared with 5% growth in the second quarter
- Ordering accounts: roughly 1,700 clinics, up about 8% (125 net new accounts by our math)
Chief executive Harout Semerjian said "Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S." The biopharmaceutical group also presented real-world studies at medical meetings in the United States, Japan and Europe matching its clinical trial results. Reported sales rose slower than demand this quarter after outpacing demand in the second quarter.
What to watch: fourth-quarter RYTELO net product revenue against the full-year plan. By our math, hitting the top of the $220 million to $240 million range requires $70.6 million in the fourth quarter, or 17.5% growth from the third quarter.
Lower Research and Staff Costs Bring Profit
Geron cut a third of its workforce last December to align spending with its single commercial drug. That restructuring, combined with rising RYTELO revenue, pushed the blood-cancer specialist to a quarterly profit of $1.4 million, compared with an $18.4 million loss a year ago. Operating income reached $5.8 million, turning an operating margin of minus 29.4% a year ago into plus 9.6% by our math.
Research and development spending fell 23.5 percentage points of revenue from a year ago to 21.1% ($12.7 million), "primarily a result of lower personnel-related expenses and lower clinical and chemistry, manufacturing, and controls (CMC) costs". Selling, general and administrative costs — sales reps and overhead — dropped 23.3 percentage points of revenue to 59.3% ($35.7 million). Because costs fell so far, Geron lowered its full-year operating expense plan by $10 million.
What to watch: research and development spending in the fourth quarter and in the 2027 plan. Stopping the Phase 3 myelofibrosis trial should remove clinical trial bills and show how much profit the company can keep from U.S. sales.
European Launch Starts with Germany This Year
European regulators approved RYTELO for lower-risk myelodysplastic syndromes earlier, but the California company held back its rollout to protect drug pricing and control spending. Semerjian said "we have initiated a gated commercial launch to bring RYTELO to targeted EU markets with availability in Germany expected by the end of the year". France will follow in 2027, giving the business its first sales outside the United States while Semerjian also evaluates outside drug candidates.
What to watch: the German reimbursement price and whether Geron hires a European distribution partner in the annual filing. Those details will show how much revenue Europe can add in 2027 without raising overhead.
🐻 Bear Case
Failed Bone Marrow Trial Leaves One Disease
Geron had been testing RYTELO in a second blood cancer, relapsed or refractory myelofibrosis (a scarring of the bone marrow), to expand the drug beyond lower-risk myelodysplastic syndromes. In the third quarter, the company stopped the Phase 3 IMpactMF trial "based on a recommendation from the independent Data Monitoring Committee (DMC) that the trial was unlikely to meet the primary endpoint of overall survival".
In the same release, Geron highlighted two medical posters from an earlier Phase 2 study on survival in that exact disease. The Phase 3 failure overrides those earlier studies, because the company stated in its risk disclosures that it "does not expect to pursue an approval pathway for imetelstat in relapsed/refractory myelofibrosis" and will not recover its investment. RYTELO now depends entirely on lower-risk myelodysplastic syndromes for growth.
What to watch: early data from smaller investigator-run studies testing RYTELO in combinations or earlier lines of treatment, due in late 2026 or 2027. Without myelofibrosis, only longer treatment duration or new combinations can expand the drug's market.
Inventory Charges Keep Hitting Production Costs
Making and shipping RYTELO usually takes very little money because Geron expensed much of its raw drug supply before regulators approved it. In the first quarter of 2026, cost of goods sold — the direct cost of making and distributing the product — was $1.7 million, or 3.3% of revenue by our math. In the second quarter, that line jumped to $9.2 million because of inventory write-offs.
The charge repeated in the third quarter. Cost of goods sold reached $6.1 million, or 10.1% of revenue, up 7.8 percentage points from 2.2% ($1.0 million) a year ago. Geron said the increase was "primarily due to non-cash inventory-related expenses". Two straight quarters of elevated charges cut gross margin to 89.9% from 97.8% a year ago and suggest that stored drug batches are expiring before patients use them.
What to watch: the inventory footnote in the third-quarter 10-Q filing. It will show the exact dollar write-off and how much of the remaining inventory balance faces expiration.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new numbers in the third-quarter press release because management saves commercial mix and legal tables for the call and quarterly filing.
- Gross-to-net discounts (rebates and fees subtracted from list price): not in the release; the 10-Q filing will show if discounts stayed in the low-to-mid 20% range.
- Share of new patients starting in first- or second-line care: not in the release after reaching 34% last quarter; call remarks will show if earlier-line use grew.
- Treatment duration: still unmeasured in the press release; any real-world persistence figure on the call would test whether patients stay on the drug longer.
- Shareholder lawsuits over early launch statements: no update in the release; the 10-Q legal footnote will report any court rulings.
💲 Other KPIs
Total cash and marketable securities rose by $12.5 million from last quarter, reversing three straight quarters of cash burn. The balance stood at $421.5 million a year ago, fell to $401.1 million at year-end, and reached $326.9 million in the second quarter. Geron said its cash and U.S. sales will fund operations for the foreseeable future.
Interest expense on Geron's debt and royalty financing stood at $7.2 million, or 12.0% of revenue by our math, down from $8.6 million a year ago and flat with $7.1 million in the first and second quarters. Interest income on cash holdings brought in $3.0 million, leaving a net interest cost of $4.2 million that absorbed most of the quarter's operating profit.
Diluted shares rose 1.0% from 667.1 million a year ago and 0.5% from 670.7 million last quarter. Because the biopharmaceutical company earned a net profit this quarter, diluted shares included 1.8 million shares from employee stock plans and warrants above the 672.3 million basic share count.
🔮 Guidance
Unchanged. Geron still expects sales "at the mid-to-high end of the $220 million to $240 million range", or about 25.3% growth at the middle of the range by our math. With $169.4 million booked in the first nine months, the $230 million middle leaves $60.6 million for the fourth quarter (+0.9% from Q3, +26.3% from a year ago), while the $240 million top implies $70.6 million (+17.5% from Q3).
Lowered by $10 million (a better cost outlook). The middle of the range now calls for an 11.7% drop in full-year spending from 2025's $254.7 million by our math. After $176.0 million of total costs and operating expenses in the first nine months, the $225 million middle leaves $49.0 million for the fourth quarter, down from $54.4 million in the third quarter.
❓ Key Questions
What caused a second quarter of inventory charges?
Cost of goods sold stayed high at $6.1 million after jumping to $9.2 million in the second quarter, both times from non-cash inventory expenses. Investors need to know how much of the remaining inventory faces expiration.
How much will stopping IMpactMF cut 2027 R&D?
Discontinuing the Phase 3 myelofibrosis trial removes a major clinical study. Management has not said how much wind-down expense remains in the fourth quarter or what the quarterly research budget will look like in 2027.
Why did revenue grow 5% when demand grew 10%?
In the second quarter, product revenue grew 11% on 5% demand growth; in the third quarter, the gap flipped to 4.6% revenue growth on 10% demand. The call should explain whether wholesaler inventory swings or bigger price discounts caused the gap.
Did earlier-line patient share rise above 34%?
First- and second-line patients made up 34% of starts over the prior 12 months as of last quarter. Because the press release omitted this figure, investors need the third-quarter reading to see if community doctors are prescribing RYTELO earlier.